Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: August 2011

3 - Corticobasal degeneration

References

1. Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967; 92: 23–6.
2. Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18(1): 20–33.
3. Case records of the Massachusetts General Hospital. weekly clinicopathological exercises. case 38–1985. A 66-year-old man with progressive neurologic deterioration. N Engl J Med 1985; 313(12): 739–48.
4. Riley DE, Lang AE, Lewis A et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40(8): 1203–12.
5. Boeve BF, Maraganore DM, Parisi JE et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999; 53(4): 795–800.
6. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54(Suppl 5): S15–19.
7. Soliveri P, Piacentini S, Girotti F. Limb apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2005; 64(3): 448–53.
8. Leiguarda R, Lees AJ, Merello M, Starkstein S, Marsden CD. The nature of apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry 1994; 57(4): 455–9.
9. Denny-Brown D. The nature of apraxia. J Nerv Ment Dis 1958; 126(1): 9–32.
10. Fitzgerald DB, Drago V, Jeong Y, Chang YL, White KD, Heilman KM. Asymmetrical alien hands in corticobasal degeneration. Mov Disord 2007; 22(4): 581–4.
11. Graham NL, Bak T, Patterson K, Hodges JR. Language function and dysfunction in corticobasal degeneration. Neurology 2003; 61(4): 493–9.
12. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53(9): 1969–74.
13. Kumar R, Bergeron C, Pollanen M, Lang AE. Cortical-basal ganglionic degeneration. In: Jankovic J, Tolosa E, eds. Parkinson’s Disease and Movement Disorders. 3rd ed. Baltimore, MD: William & Wilkins; 1998. 297–316.
14. Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003; 18(11): 1224–32.
15. Pillon B, Blin J, Vidailhet M et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995; 45(8): 1477–83.
16. Kompoliti K, Goetz CG, Boeve BF et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998; 55(7): 957–61.
17. Carella F, Ciano C, Panzica F, Scaioli V. Myoclonus in corticobasal degeneration. Mov Disord 1997; 12(4): 598–603.
18. Vidailhet M, Rivaud-Pechoux S. Eye movement disorders in corticobasal degeneration. Adv Neurol 2000; 82: 161–7.
19. Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000; 54(5): 1029–32.
20. Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65(5): 717–21.
21. Nagaoka K, Ookawa S, Maeda K. A case of corticobasal degeneration presenting with visual hallucination. Rinsho Shinkeigaku 2004; 44(3): 193–7.
22. Thumler BH, Urban PP, Davids E et al. Dysarthria and pathological laughter/crying as presenting symptoms of corticobasal-ganglionic degeneration syndrome. J Neurol 2003; 250(9): 1107–8.
23. Mendez MF. Corticobasal ganglionic degeneration with balint’s syndrome. J Neuropsychiatry Clin Neurosci 2000; 12(2): 273–5.
24. Okuda B, Kodama N, Tachibana H, Sugita M, Tanaka H. Visuomotor ataxia in corticobasal degeneration. Mov Disord 2000; 15(2): 337–40.
25. DePold Hohler A, Ransom BR, Chun MR, Troster AI, Samii A. The youngest reported case of corticobasal degeneration. Parkinsonism Relat Disord 2003; 10(1): 47–50.
26. Wenning GK, Litvan I, Jankovic J et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64(2): 184–9.
27. Koyama M, Yagishita A, Nakata Y, Hayashi M, Bandoh M, Mizutani T. Imaging of corticobasal degeneration syndrome. Neuroradiology 2007; 49(11): 905–12.
28. Tokumaru AM, Saito Y, Murayama S et al. Imaging-pathologic correlation in corticobasal degeneration. AJNR Am J Neuroradiol 2009; 30(10): 1884–92.
29. Boxer AL, Geschwind MD, Belfor N et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63(1): 81–6.
30. Grossman M, McMillan C, Moore P et al. What’s in a name: voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer’s disease, frontotemporal dementia and corticobasal degeneration. Brain 2004; 127(Pt 3): 628–49.
31. Rizzo G, Martinelli P, Manners D et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and parkinson’s disease. Brain 2008; 131(Pt 10): 2690–700.
32. Ukmar M, Moretti R, Torre P, Antonello RM, Longo R, Bava A. Corticobasal degeneration: structural and functional MRI and single-photon emission computed tomography. Neuroradiology 2003; 45(10): 708–12.
33. Tedeschi G, Litvan I, Bonavita S et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson’s disease and corticobasal degeneration. Brain 1997; 120(Pt 9): 1541–52.
34. Vion-Dury J, Rochefort N, Michotey P, Planche D, Ceccaldi M. Proton magnetic resonance neurospectroscopy and EEG cartography in corticobasal degeneration: correlations with neuropsychological signs. J Neurol Neurosurg Psychiatry 2004; 75(9): 1352–5.
35. Nagahama Y, Fukuyama H, Turjanski N et al. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord 1997; 12(5): 691–6.
36. Gerhard A, Watts J, Trender-Gerhard I et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 2004; 19(10): 1221–6.
37. Nagasawa H, Tanji H, Nomura H et al. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. J Neurol Sci 1996; 139(2): 210–7.
38. Laureys S, Salmon E, Garraux G et al. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol 1999; 246(12): 1151–8.
39. Klaffke S, Kuhn AA, Plotkin M et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006; 21(10): 1724–7.
40. Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 2004; 63(3): 504–9.
41. Josephs KA, Petersen RC, Knopman DS et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66(1): 41–8.
42. Urakami K, Mori M, Wada K et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett 1999; 259(2): 127–9.
43. Urakami K, Wada K, Arai H et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001; 183(1): 95–8.
44. Mitani K, Furiya Y, Uchihara T et al. Increased CSF tau protein in corticobasal degeneration. J Neurol 1998; 245(1): 44–6.
45. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson’s disease, dementia with lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2006; 250(1–2): 120–3.
46. Kanemaru K, Mitani K, Yamanouchi H. Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration. Neurosci Lett 1998; 245(2): 121–2.
47. Vanvoorst WA, Greenaway MC, Boeve BF et al. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14(4): 376–8.
48. Lu CS, Ikeda A, Terada K et al. Electrophysiological studies of early stage corticobasal degeneration. Mov Disord 1998; 13(1): 140–6.
49. Katsuse O, Iseki E, Arai T et al. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 2003; 106(3): 251–60.
50. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol 1999; 9(4): 681–93.
51. Houlden H, Baker M, Morris HR et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001; 56(12): 1702–6.
52. Mirra SS, Murrell JR, Gearing M et al. Tau pathology in a family with dementia and a P301L mutation in tau. J Neuropathol Exp Neurol 1999; 58(4): 335–45.
53. Spillantini MG, Yoshida H, Rizzini C et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol 2000; 48(6): 939–43.
54. Bugiani O, Murrell JR, Giaccone G et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999; 58(6): 667–77.
55. Rossi G, Marelli C, Farina L et al. The G389R mutation in the MAPT gene presenting as sporadic corticobasal syndrome. Mov Disord 2008; 23(6): 892–5.
56. Masellis M, Momeni P, Meschino W et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 2006; 129(Pt 11): 3115–23.
57. Spina S, Murrell JR, Huey ED et al. Corticobasal syndrome associated with the A9D progranulin mutation. J Neuropathol Exp Neurol 2007; 66(10): 892–900.
58. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: Neuropathologic and clinical heterogeneity. Neurology 1997; 48(4): 959–69.
59. Dickson DW, Bergeron C, Chin SS et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61(11): 935–46.
60. Boeve BF, Josephs KA, Drubach DA. Current and future management of the corticobasal syndrome and corticobasal degeneration. Handb Clin Neurol 2008; 89: 533–48.
61. Frucht S, Fahn S, Chin S, Dhawan V, Eidelberg D. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord 2000; 15(2): 340–3.